IRIDEX Stock (NASDAQ:IRIX)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.13

52W Range

$0.87 - $1.65

50D Avg

$1.05

200D Avg

$1.17

Market Cap

$19.50M

Avg Vol (3M)

$258.39K

Beta

0.66

Div Yield

-

IRIX Company Profile


IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

93

IPO Date

Feb 16, 1996

Website

IRIX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJan 26Dec 24Dec 23
Cyclo G Six$13.84M$12.70M$13.46M
Product and Service, Other$8.55M$8.14M$8.96M
Retina$30.28M$27.83M$29.45M

Fiscal year ends in Jan 26 | Currency in USD

IRIX Financial Summary


Jan 26Dec 24Dec 23
Revenue$52.67M$48.67M$51.87M
Operating Income$-2.57M$-8.30M$-10.01M
Net Income$-4.44M$-8.91M$-9.57M
EBITDA$-1.02M$-6.88M$-7.97M
Basic EPS$-0.26$-0.54$-0.59
Diluted EPS$-0.26$-0.54$-0.59

Fiscal year ends in Jan 26 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Mar 26, 26 | 5:00 PM
Q3 25Nov 11, 25 | 5:00 PM
Q2 25Aug 12, 25 | 5:00 PM

Peer Comparison


TickerCompany
ASBPAspire Biopharma Holdings, Inc.
COCHEnvoy Medical, Inc.
HOTHRocket One Inc.
ALURAllurion Technologies Inc.
PULMPulmatrix, Inc.
VVOSVivos Therapeutics, Inc.
NVNOenVVeno Medical Corporation
ADGMAdagio Medical Holdings, Inc.
IINNInspira Technologies Oxy B.H.N. Ltd.
PALIPalisade Bio, Inc.